Sangamo Therapeutics, Inc (SGMOQ): R&D Expense
$112.67M
Year ended 2025-12-31
$113.23M
Trailing 12 months to 2026-03-31
-23.3%
3-year compound annual growth
-9.0%
5-year compound annual growth
+5.3%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $112.67M | +1.0% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $111.52M | -52.4% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $234.06M | -6.3% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $249.90M | +8.3% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $230.82M | +27.8% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $180.65M | +23.8% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $145.92M | +27.0% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $114.87M | +74.8% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $65.73M | +0.2% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $65.62M | -2.4% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $67.20M | +17.9% | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | $56.97M | +53.8% | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | $37.04M | +16.8% | 2016-02-18, From 2013-01-01 |
| 2012-12-31 | $31.71M | -1.2% | 2015-02-25, From 2012-01-01 |
| 2011-12-31 | $32.10M | -3.2% | 2014-02-24, From 2011-01-01 |
| 2010-12-31 | $33.15M | +14.4% | 2013-02-26, From 2010-01-01 |
| 2009-12-31 | $28.98M | n/a | 2012-02-23, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $112.67M | +1.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $316.57M | +31.8% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $134.67M | +5.7% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $250.0K | -18.6% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
Compare SGMOQ, KYMR, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗